 |
VasoMedical to Showcase EECP® Therapy, BIOX and Other New Products at the 2014 Arab Health Exhibition & Congress |
WESTBURY, N.Y. – January 10, 2014 – VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® systems, the gold standard of ECP therapy, announced today that it will be exhibiting at the Arab Health Exhibition & Congress from January 27-31, 2014 in Dubai, United Arab Emirates.
The Arab Health Exhibition & Congress is the world's longest running healthcare exhibition and congress and the largest health conference in the Middle East and Asia. In previous years, this event has attracted more than 4,000 companies from across the globe, along with an audience of more than 85,000 medical professionals, distributors, dealers and suppliers from 153 countries. The exhibition itself features products and services on display from the world's leading manufacturers, wholesalers, and distributors.
The VasoMedical exhibit will be located at Booth #CB61 in the Concourse Hall at the Dubai International Convention & Exhibition Centre. The Company will present its core technology, EECP® Therapy, a leading non-invasive treatment for cardiovascular disease, BIOX ECG Holter and Ambulatory Blood Pressure Monitoring devices as well as its line of patient monitoring products, including the new MobiCare® wireless multiparameter patient monitor.
“This is our third consecutive year exhibiting at the Arab Health Exhibition & Congress and once again it is a fantastic opportunity for us to take part in a highly regarded conference in an important and burgeoning market” said Larry Liebman, Vice President of Sales & Marketing at VasoMedical. “The conference provides VasoMedical with an excellent opportunity to generate greater awareness of EECP® Therapy, our BIOX product line as well as introduce and showcase new products. Arab Health is the first show of our 2014 schedule. It is one of many activities designed to educate the global medical industry's leaders on the benefits of VasoMedical products and our additional capabilities as a developer, provider and OEM manufacturer for new technologies.”
The Middle East is one of the largest and growing markets in the world for medical equipment and healthcare products in which the healthcare industry is valued at $80 billion. The region also serves as a scientific and educational hub for professionals looking to share knowledge, best-practices and learn about the latest trends in the Middle Eastern and global healthcare industries.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273
swolf@kcsa.com / aherweg@kcsa.com